title: Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.
abstract: In a recent expert meeting, Swedish recommendations for the treatment of hepatitis C virus (HCV) infection were updated. An interferon-free combination of direct-acting antiviral agents is considered and indicated for all patients with chronic HCV infection, but the ability to treat all is limited primarily by high cost of medication. The group of patients prioritized for therapeutic intervention has been extended to also include fertile women desiring to become pregnant. A more thorough discussion of treatment for people who inject drugs (PWIDs) in order to diminish transmission is included, and the clinical significance of baseline NS5A resistance associated variants (RAVs), also known as resistance associated substitutions (RASs), for the treatment of HCV genotype 1a or 3 infection is discussed.
authors.affiliation: a Department of Infectious Diseases , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Martin
authors.initials: M
authors.lastname: Lagging
authors.affiliation: a Department of Infectious Diseases , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.|b Swedish Reference Group for Antiviral Therapy (RAV) , Sweden.
authors.forename: Rune
authors.initials: R
authors.lastname: Wejstål
authors.affiliation: a Department of Infectious Diseases , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Norkrans
authors.affiliation: c Medical Products Agency , Uppsala, Sweden.
authors.forename: Olle
authors.initials: O
authors.lastname: Karlström
authors.affiliation: d Department of Infectious Diseases , Karolinska University Hospital , Stockholm, Sweden.
authors.forename: Soo
authors.initials: S
authors.lastname: Aleman
authors.affiliation: d Department of Infectious Diseases , Karolinska University Hospital , Stockholm, Sweden.
authors.forename: Ola
authors.initials: O
authors.lastname: Weiland
authors.affiliation: e Transplant Institute, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Castedal
authors.affiliation: a Department of Infectious Diseases , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Johan
authors.initials: J
authors.lastname: Westin
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D006526:Hepatitis C / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology / Q000821:virology; D006801:Humans; D017410:Practice Guidelines as Topic; D013548:Sweden
chemical_list: D000998:Antiviral Agents
keywords: Children; Chronic kidney disease; Direct-acting antiviral agents; Genotype; Guidelines; HIV co-infection; Hepatitis C virus; People who inject drugs; Resistance associated substitutions; Resistance associated variants